Federal Register / Vol. 65, No. 239 / Tuesday, December 12, 2000 / Notices 77559

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Docket 65–2000]

Foreign-Trade Zone 27—Boston,

Massachusetts; Application for

Subzone, AstraZeneca LP

(Pharmaceutical Products),

Westborough, MA

An application has been submitted to

the Foreign-Trade Zones Board (the

Board) by the Massachusetts Port

Authority, grantee of FTZ 27, requesting

special-purpose subzone status for the

pharmaceutical manufacturing plant of

AstraZeneca LP in Westborough,

Massachusetts. The application was

submitted pursuant to the provisions of

the Foreign-Trade Zones Act, as

amended (19 U.S.C. 81a–81u), and the

regulations of the Board (15 CFR part

400). It was formally filed on November

28, 2000.

AstraZeneca LP is a subsidiary of

AstraZeneca PLC, a global prescription

pharmaceutical manufacturer, formed in

1999 by a merger between Zeneca Group

PLC (U.K.) and Astra AB (Sweden).

The Westborough plant (532,543 sq.

ft./13 bldgs. on 83.3 acres) is located at

50 and 53 Otis Street, Westborough,

Massachusetts. The facility (650

employees) produces finished

pharmaceutical products and their

intermediates, including XYLOCAINE,

POLOCAINE, NAROPIN,

SENSORCAINE anesthetics, and

PULMICORT RESPULES, for the

treatment of asthma. Foreign-sourced

materials will account for, on average,

70 percent of material value, and

include items from the following

general categories: Gums, starches,

waxes, vegetable extracts, mineral oils,

chemically pure sugars, empty capsules,

protein concentrates, prepared animal

feed, mineral products, inorganic acids,

chlorides, clorates, sulfites, sulfates,

phosphates, cyanides, silicates,

radioactive chemicals, rare-earth metal

compounds, hydroxides, hydrazine and

hydroxylamine, chlorides, natural

magnesium phosphates and carbonates,

cyclic and acyclic hydrocarbons,

alcohols, phenols and peroxides, esters,

epoxides, acetals, aldehydes, ketone

function compounds, mono- and

polycarboxylic acids, phosphoric esters,

amine-, carboxymide, nitrile- and

oxygen-function compounds,

heterocyclic compounds, sulfonamides,

insecticides, rodenticides, fungicides

and herbicides, fertilizers, vitamins,

hormones, antibiotics, enzymes,

essential oils, albumins, gelatins,

activated carbon, residual lyes, acrylic

polymers, color lakes, soaps and

detergents, protein concentrates,

gypsum, anhydrite and plasters,

petroleum jelly, paraffin and waxes,

sulfuric acid, other inorganic acids or

compounds of nonmetals, ammonia,

zinc oxide, titanium oxides, fluorides,

chlorates, sulfates, salts of oxometallic

acids, radioactive chemical elements,

compounds of rare earth metals,

derivatives of phenols or peroxides,

acetals and hemiacetals, phosphoric

esters and their salts, diazo-compounds,

glands for therapeutic uses, wadding,

gauze and bandages, pharmaceutical

glaze, hair preparations, lubricating

preparations, albumins, prepared glues

and adhesives, catalytic preparations,

diagnostic or laboratory reagents,

prepared binders, acrylic polymers, selfadhesive plates and sheets, other

articles of vulcanized rubber, plastic

cases, cartons, boxes, printed books,

brochures and similar printed matter,

carboys, bottles, and flasks, stoppers,

caps, and lids, aluminum foil, tin plates

and sheets, taps, cocks and valves, and

medical instruments and appliances.

Zone procedures would exempt

AstraZeneca from Customs duty

payments on foreign materials used in

production for export. On domestic

sales, the company would be able to

choose the duty rates that apply to the

finished products (duty-free) rather than

the duty rates that would otherwise

apply to the foreign-sourced materials

noted above (duty-free to 20.0 percent).

Although at the outset, 100 percent of

the production of ZD–0473, a

developmental drug for the treatment of

cancer, will be exported, it is expected

that future zone savings would

primarily involve choosing the finished

product duty rate on ZD–0473, (HTSUS

3004.90.9015—duty-free), rather than

the rate for a foreign-sourced active

ingredient (HTSUS 2843.90.0000—

3.7%). The application indicates that

the savings from zone procedures will

help improve the plant’s international

competitiveness.

In accordance with the Board’s

regulations, a member of the FTZ Staff

has been designated examiner to

investigate the application and report to

the Board.

Public comment is invited from

interested parties. Submissions (original

and 3 copies) shall be addressed to the

Board’s Executive Secretary at the

address below. The closing period for

their receipt is February 10, 2001.

Rebuttal comments in response to

material submitted during the foregoing

period may be submitted during the

subsequent 15-day period (to February

25, 2001).

A copy of the application and

accompanying exhibits will be available

for public inspection at each of the

following locations:

U.S. Department of Commerce, Export

Assistance Center, 164 Northern

Avenue, World Trade Center, Suite

307, Boston, Massachusetts 02210.

Office of the Executive Secretary,

Foreign-Trade Zones Board, U.S.

Department of Commerce, Room

4008, 14th & Pennsylvania Avenue,

NW., Washington, DC 20230.

Dated: November 30, 2000.

Dennis Puccinelli,

Executive Secretary.

[FR Doc. 00–31492 Filed 12–11–00; 8:45 am]

BILLING CODE 3510–DS–P

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[Docket 66–2000]

Foreign-Trade Zone 199—Texas City,

Texas; Application for Subzone, ISP

Technologies Inc. (Chemical Plant),

Texas City, TX

An application has been submitted to

the Foreign-Trade Zones Board (the

Board) by the Texas City Foreign-Trade

Zone Corporation, grantee of FTZ 199,

requesting special-purpose subzone

status for the chemical plant facilities of

ISP Technologies Inc., located in Texas

City, Texas. The application was

submitted pursuant to the provisions of

the Foreign-Trade Zones Act, as

amended (19 U.S.C. 81a–81u), and the

regulations of the Board (15 CFR part

400). It was formally filed on November

28, 2000.

The facility is located at 4501

Attwater Avenue, Texas City, Texas.

The application is requesting the use of

zone procedures only for the portion of

the facility that processes butanediol

(B1D) into butyrolactone (BLO). This

portion of the facility (2.2 acres, 170

employees) has the capacity to produce

140,000 pounds per day of BLO (HTS

2932.29.50 and 3824.90.47; duty rate

3.7%). All of the B1D is sourced from

abroad (HTS 2905.39.10; duty rate

7.9%).

FTZ procedures would exempt ISP

from Customs duty payments on the

foreign components used in export

production. Some 35 percent of the BLO

produced from the imported B1D in

1999 was exported. On its domestic

sales, ISP would be able to choose the

duty rates during Customs entry

procedures that apply to BLO (3.7%) for

the foreign input noted above. The

request indicates that the savings from

FTZ procedures would help improve